ViaDor-GLP1 agonist: Phase Ib data

Data from a 4-way crossover Phase Ib trial in 14 Type II diabetics showed that single doses of 3 patch formulations of once-daily ViaDor-GLP1 agonist were well tolerated, with an extended PK profile c...